See more : Jubilee Gold Exploration Ltd. (JBULF) Income Statement Analysis – Financial Results
Complete financial analysis of Yield10 Bioscience, Inc. (YTEN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Yield10 Bioscience, Inc., a leading company in the Agricultural Inputs industry within the Basic Materials sector.
You may be interested
- Tecnos Japan Incorporated (3666.T) Income Statement Analysis – Financial Results
- Tethys Oil AB (publ) (TETY.ST) Income Statement Analysis – Financial Results
- Logan Group Company Limited (LPHHF) Income Statement Analysis – Financial Results
- Frasers Property (Thailand) Public Company Limited (FPT.BK) Income Statement Analysis – Financial Results
- Kuo Toong International Co., Ltd. (8936.TWO) Income Statement Analysis – Financial Results
Yield10 Bioscience, Inc. (YTEN)
About Yield10 Bioscience, Inc.
Yield10 Bioscience, Inc., an agricultural bioscience company, engages in developing technologies to enable step-change increases in crop yield in the United States and Canada. The company, through its Trait Factory, a trait gene discovery platform develops enhanced oilseed Camelina sativa for the production of proprietary seed products; and discovers high value genetic traits for the agriculture and food industries. Yield10 Bioscience, Inc. has license agreements with GDM Seeds; J. R. Simplot; Forage Genetics International, LLC; and Bayer AG. The company was formerly known as Metabolix, Inc. and changed its name to Yield10 Bioscience, Inc. in January 2017. Yield10 Bioscience, Inc. was incorporate in 1992 and is headquartered in Woburn, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 60.00K | 450.00K | 614.00K | 799.00K | 806.00K | 556.00K | 944.00K | 1.16M | 2.59M | 2.80M | 5.39M | 42.32M | 1.43M | 448.00K | 1.43M | 1.56M | 1.68M | 4.59M | 2.78M | 3.68M | 2.38M | 1.99M |
| Cost of Revenue | 290.00K | 656.00K | 578.00K | 5.22M | 4.85M | 4.78M | 4.60M | 5.67M | 660.00K | 1.48M | 3.03M | 1.43M | 24.45M | 23.67M | 24.47M | 24.67M | 19.90M | 11.24M | 5.98M | 5.43M | 0.00 | 0.00 |
| Gross Profit | -230.00K | -206.00K | 36.00K | -4.42M | -4.04M | -4.23M | -3.65M | -4.51M | 1.93M | 1.32M | 2.37M | 40.89M | -23.02M | -23.23M | -23.05M | -23.11M | -18.22M | -6.65M | -3.20M | -1.75M | 2.38M | 1.99M |
| Gross Profit Ratio | -383.33% | -45.78% | 5.86% | -553.32% | -501.49% | -760.25% | -386.97% | -389.21% | 74.56% | 47.07% | 43.90% | 96.63% | -1,615.44% | -5,184.15% | -1,617.26% | -1,486.30% | -1,082.47% | -144.77% | -115.04% | -47.53% | 100.00% | 100.00% |
| Research & Development | 8.32M | 7.75M | 6.20M | 5.36M | 4.85M | 4.78M | 4.60M | 5.67M | 16.57M | 17.34M | 19.13M | 23.18M | 0.00 | 0.00 | 0.00 | 24.67M | 19.90M | 11.24M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 6.15M | 6.15M | 6.11M | 5.05M | 4.55M | 5.09M | 5.63M | 5.74M | 9.11M | 10.81M | 13.74M | 14.11M | 15.84M | 15.71M | 15.68M | 15.78M | 15.60M | 10.88M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.15M | 6.15M | 6.11M | 5.05M | 4.55M | 5.09M | 5.63M | 5.74M | 9.11M | 10.81M | 13.74M | 14.11M | 15.84M | 15.71M | 15.68M | 15.78M | 15.60M | 10.88M | 3.83M | 3.25M | 0.00 | 2.64M |
| Other Expenses | 0.00 | 41.00K | -3.00K | 83.00K | 21.00K | 134.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 14.48M | 13.90M | 12.31M | 10.41M | 9.40M | 9.88M | 10.23M | 11.41M | 25.68M | 28.15M | 32.87M | 37.29M | 15.84M | 15.71M | 15.68M | 40.45M | 35.50M | 22.11M | 3.83M | 3.25M | 0.00 | 7.05M |
| Cost & Expenses | 14.48M | 13.90M | 12.31M | 10.41M | 9.40M | 9.88M | 10.23M | 11.41M | 26.34M | 29.63M | 35.90M | 38.71M | 40.29M | 39.39M | 40.15M | 40.45M | 35.50M | 22.11M | 9.81M | 8.68M | 0.00 | 7.05M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 96.00K | 158.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 76.00K | 0.00 | 0.00 | 0.00 | 5.94M | 1.47M | 109.36K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 13.02M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -80.00K | 0.00 | 772.00K | 2.89M | 0.00 | 5.00K | 10.14K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 290.00K | 656.00K | 578.00K | 611.00K | 1.83M | 784.00K | 206.00K | 177.00K | 265.00K | 507.00K | 928.00K | 1.30M | 1.51M | 1.65M | 2.73M | 3.73M | 1.45M | 964.00K | 314.57K | 265.25K | 0.00 | 0.00 |
| EBITDA | -14.13M | -13.19M | -11.47M | -9.43M | -8.39M | -9.12M | -9.08M | -10.07M | -12.35M | -26.32M | -27.61M | 4.90M | -37.35M | -37.29M | -36.00M | -35.16M | -32.37M | -16.56M | -6.71M | -4.73M | 2.38M | -5.06M |
| EBITDA Ratio | -23,545.00% | -2,930.67% | -1,982.41% | -1,101.75% | -609.93% | -1,640.83% | -949.58% | -836.50% | -907.48% | -942.25% | -547.26% | 11.58% | -2,621.33% | -8,324.11% | -2,525.96% | -2,261.16% | -1,923.05% | -360.78% | -216.11% | -128.73% | 100.00% | -254.60% |
| Operating Income | -14.42M | -13.45M | -11.69M | -9.61M | -8.60M | -9.32M | -9.28M | -10.25M | -23.74M | -26.83M | -30.50M | 3.60M | -38.86M | -38.94M | -38.73M | -38.89M | -33.82M | -17.52M | -7.02M | -5.00M | 2.38M | -5.06M |
| Operating Income Ratio | -24,028.33% | -2,989.11% | -1,904.23% | -1,202.63% | -1,066.50% | -1,676.08% | -983.37% | -884.21% | -915.30% | -958.18% | -565.48% | 8.51% | -2,727.09% | -8,691.74% | -2,717.82% | -2,501.09% | -2,009.27% | -381.79% | -252.59% | -135.94% | 100.00% | -254.60% |
| Total Other Income/Expenses | -38.00K | 41.00K | 697.00K | -541.00K | -4.61M | 134.00K | -113.00K | -38.00K | 29.00K | 61.00K | -4.00K | 27.00K | 76.00K | 136.00K | 0.00 | 0.00 | 5.94M | 1.46M | -699.64K | 0.00 | -2.38M | 5.06M |
| Income Before Tax | -14.46M | -13.41M | -11.00M | -10.15M | -13.21M | -9.19M | -9.40M | -10.29M | -23.68M | -26.77M | -30.51M | 3.63M | -38.79M | -38.80M | 0.00 | 0.00 | -27.88M | -16.06M | -7.72M | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -24,091.67% | -2,980.00% | -1,790.72% | -1,270.34% | -1,638.96% | -1,651.98% | -995.34% | -887.49% | -912.91% | -956.00% | -565.55% | 8.58% | -2,721.75% | -8,661.38% | 0.00% | 0.00% | -1,656.27% | -349.93% | -277.76% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 156.00K | 36.00K | 56.00K | -254.00K | 104.00K | 113.00K | -1.10M | -62.00K | 2.71M | 4.00K | 0.00 | 0.00 | 0.00 | -772.00K | -2.89M | 0.00 | 0.00 | 600.79K | 54.31K | 6.64M | 5.19M |
| Net Income | -14.46M | -13.57M | -11.03M | -10.21M | -12.96M | -9.19M | -9.40M | -7.60M | -23.68M | -29.53M | -30.51M | 3.63M | -38.79M | -38.80M | -37.96M | -36.01M | -27.88M | -16.06M | -7.63M | -5.05M | -6.64M | -5.19M |
| Net Income Ratio | -24,091.67% | -3,014.67% | -1,796.58% | -1,277.35% | -1,607.44% | -1,651.98% | -995.34% | -656.08% | -912.91% | -1,054.79% | -565.55% | 8.58% | -2,721.75% | -8,661.38% | -2,663.65% | -2,315.43% | -1,656.27% | -349.93% | -274.20% | -137.42% | -278.62% | -260.83% |
| EPS | -43.66 | -66.25 | -55.95 | -103.21 | -851.98 | -887.78 | -2.77K | -2.65K | -9.18K | -27.97K | -51.50K | 277.48 | -72.21K | -84.34K | -94.26K | -91.74K | -73.75K | -172.10K | -149.23K | -79.89K | -158.62K | -100.88K |
| EPS Diluted | -43.66 | -66.25 | -55.95 | -103.21 | -851.98 | -887.78 | -2.77K | -2.65K | -9.18K | -27.97K | -51.50K | 277.48 | -72.21K | -84.34K | -94.26K | -91.74K | -73.75K | -172.10K | -121.96K | -79.89K | -158.62K | -100.88K |
| Weighted Avg Shares Out | 331.10K | 204.77K | 197.16K | 98.89K | 15.21K | 10.35K | 3.39K | 2.87K | 2.58K | 1.06K | 592.33 | 588.00 | 537.10 | 460.06 | 402.69 | 392.46 | 377.99 | 93.33 | 51.10 | 63.27 | 41.86 | 51.43 |
| Weighted Avg Shares Out (Dil) | 331.10K | 204.77K | 197.16K | 98.89K | 15.21K | 10.35K | 3.39K | 2.87K | 2.58K | 1.06K | 592.33 | 589.07 | 537.10 | 460.06 | 402.69 | 392.46 | 377.99 | 93.33 | 62.52 | 63.27 | 41.86 | 51.43 |
Yield10 Bioscience Chief Science Officer Dr. Kristi Snell to Present on Advances Using Camelina Platform to Produce PHA Bioplastic at 2021 Synthetic Biology: Engineering, Evolution and Design Virtual Conference
WOBURN, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today announced that its Chief Science Officer Dr. Kristi Snell will present during the 2021 Synthetic Biology: Engineering, Evolution & Design (SEED) conference, taking...
Yield10 Bioscience to Present at the LD Virtual Invitational XI on June 9, 2021
WOBURN, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq: YTEN), an agricultural bioscience company, today announced that Oliver Peoples, Ph.D., President and Chief Executive Officer of Yield10, will give a corporate presentation at the LD Micro Virtual...
Yield10 Bioscience's (YTEN) CEO Oliver Peoples on Q1 2021 Results - Earnings Call Transcript
Yield10 Bioscience's (YTEN) CEO Oliver Peoples on Q1 2021 Results - Earnings Call Transcript
Yield10 Bioscience to Announce First Quarter 2021 Financial Results and Host a Conference Call on Tuesday, May 11, 2021
WOBURN, Mass., May 04, 2021 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today announced that the Company will report its first quarter 2021 financial results and provide a corporate update on Tuesday, May 11, 2021.
Yield10 Bioscience's (YTEN) CEO Oliver Peoples on Q4 2020 Results - Earnings Call Transcript
Yield10 Bioscience's (YTEN) CEO Oliver Peoples on Q4 2020 Results - Earnings Call Transcript
Yield10 Bioscience Announces Fourth Quarter and Full Year 2020 Financial Results
Management will host a conference call today at 4:30 p.m. (ET) to review financial results and provide a corporate update Management will host a conference call today at 4:30 p.m. (ET) to review financial results and provide a corporate update
Yield10 Bioscience to Announce Fourth Quarter and Full Year 2020 Financial Results and Host a Conference Call on Tuesday, March 16, 2021
WOBURN, Mass., March 09, 2021 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today announced that the Company will report its fourth quarter and full year 2020 financial results and provide a corporate update on Tuesday, March...
Yield10 Bioscience to Present at Bank of America 2021 Virtual Global Agriculture & Materials Conference on March 4, 2021
WOBURN, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today announced it will be featured as a presenting company at the Bank of America 2021 Virtual Global Agriculture & Materials Conference being held...
Yield10 Bioscience Announces Warrant Exercises for Proceeds of $3.8 million
WOBURN, Mass., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today announced that it has received proceeds of approximately $3.8 million from the exercise of 472,099 warrants exercised between January 1, 2021 and February...
Yield10 Bioscience Announces Closing of $12.7 Million Public Offering
WOBURN, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq: YTEN), an agricultural bioscience company, today announced the closing of its previously announced underwritten public offering of 1,040,000 shares of its common stock at a public offering price...
Source: https://incomestatements.info
Category: Stock Reports